Oraya Therapeutics

Saving Your Sight: There Is Hope and Help

All too often we take our sight for granted, yet, of all the senses, vision is widely regarded as the richest and most complex. Imagine a world that was once clear — now foggy and blurry, especially in dim light. If you or someone you love suffers from wet age-related macular degeneration (AMD), you know these symptoms all too well.

AMD is a progressive disease usually occurring at age 55 or older, with multiple environmental and genetic factors. It is divided into early (dry) and late (wet) stages. For seniors throughout the industrialized world, AMD is the primary cause of vision loss, and it can have devastating consequences on your life and the lives of those you love.

Wet AMD, one late form of the disease, attacks the macula of the eye, which is the area of our sharpest central vision. It occurs with the growth of abnormal blood vessels, or choroidal neovascularization (CNV), under the macula. These abnormal vessels leak fluid and blood into the tissue at the back of the eye, resulting in inflammation and scarring of the retina, which lead to distortion and eventual permanent loss of central vision. In fact, if untreated, wet AMD can rapidly damage the macula and result in near-total central blindness within two years of onset.

Although the wet form of AMD accounts for only 10 to 15 percent of all AMD worldwide, the risk of severe sight loss is much greater with this condition. According to the AMD Alliance International, wet AMD is responsible for 90 percent of the cases of severe vision loss associated with AMD. While symptoms and treatment options vary, depending on the type of AMD and location of the leakages, there is presently no cure for AMD. The good news — current therapies involving anti-VEGF injections, such as Lucentis®, are successful at preserving the sight of wet AMD patients. However, the injections are needed frequently. Such a regimen can be very difficult to continue indefinitely.

Now, there is a novel treatment option for wet AMD. The innovative Oraya Therapy, offers patients a non-invasive approach to treating wet AMD. The procedure is intended as a one-time treatment that takes about 20 minutes, and the patients can go home shortly thereafter.

Before starting any treatment, we suggest educating yourself on the disease and your therapeutic options, and discussing the alternatives with your ophthalmologist. This section of our site provides an overview of AMD, how it is detected, diagnosed, and treated, along with a description of Oraya Therapy and links to various AMD support organizations.

If you have additional questions, please send an e-mail to info@orayainc.com.

Back To Top

© 2014 All rights reserved. Oraya Therapeutics, Inc. The IRay® is a CE-marked medical device. The IRay is not available for sale in the United States. For additional details, including safety and risk information, please see the ORAYA THERAPY section of this website. Oraya, Oraya Therapy, IRay and I-Guide are either trademarks or registered trademarks of Oraya Therapeutics, Inc. in the United States and other countries.